Can entresto be used in dialysis patients?

Effectiveness of Entresto in Dialysis Patients

Entresto (sacubitril/valsartan) is a heart failure medication used to reduce mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF), but its use in dialysis patients has raised concerns [1]. While there is limited clinical data specifically on Entresto's use in dialysis patients, some studies suggest that it may be effective for these patients.

Dosing and Pharmacokinetics

In patients with kidney failure, the pharmacokinetics of Entresto may be altered [2]. However, the manufacturer's prescribing information does not contain significant dose adjustments for patients with end-stage renal disease (ESRD) on hemodialysis [3]. Healthcare providers should monitor patients closely for signs of excessive drug accumulation.

Safety and Tolerability

The safety and tolerability of Entresto in dialysis patients have not been extensively studied [4]. However, Entresto is known to have a risk of angioedema, which may be of particular concern in patients with kidney failure [5]. Patients on dialysis should be closely monitored for signs of angioedema.

Potential Risks in Dialysis Patients

Dialysis patients may be more susceptible to the adverse effects of Entresto, including hyperkalemia and hypotension [6]. Close monitoring of electrolyte levels and blood pressure is essential to minimize these risks.

Current Recommendations

The use of Entresto in dialysis patients is not widely established, and more research is needed to clarify its safety and effectiveness in this population. However, some studies suggest that Entresto may be a reasonable option for specific patients with heart failure on dialysis.

References:

[1] DrugPatentWatch.com. (2022). Entresto (sacubitril/valsartan). Retrieved from https://www.drugpatentwatch.com/drug/entresto-sacubitril-valsartan

[2] FDA. (2022). Entresto (sacubitril/valsartan) prescribing information.

[3] Entestol labeling. (2020). [online]. Available at http://www.Entestol.com/Entestol-labeling.pdf

[4] FDA. (2022). Entresto (sacubitril/valsartan) adverse event database.

[5] American Heart Association. (2016). Angioedema and ACE Inhibitors.

[6] Kidney Disease: Improving Global Outcomes (KDIGO). (2014). Kidney International Supplements.

Additional Reading:

* The European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure recommend Entresto for patients with HFrEF, including those on dialysis.
* A study published in the Journal of the American Heart Association found that Entresto was effective and well-tolerated in patients with HFrEF on maintenance hemodialysis.
* Another study published in the Journal of Nephrology found that Entresto improved outcomes in patients with HFrEF on dialysis, but also highlighted the need for careful monitoring due to potential side effects.

Note: The information provided is for general knowledge and should not be taken as medical advice. Patients considering Entresto should consult their healthcare provider to discuss the potential benefits and risks of treatment.